Transcatheter Cardiovascular Therapeutics (TCT)

The Transcatheter Cardiovascular Therapeutics (TCT) conference is the Cardiovascular Research Foundation's (CRF) annual scientific symposium and the largest conference focused on interventional cardiovascular medicine. TCT includes seminars on all areas of intervention cardiology, structural heart, vascular in interventions, peripheral artery disease, and other procedures in the cath lab.

RSS icon

New data highlight long-term benefits of HeartFlow’s AI-based CAD evaluations

HeartFlow kicked off TCT 2024 by sharing new research on the long-term impact of its FFRCT Analysis and Plaque Analysis software.

HeartFlow sharing new data on AI-enabled CAD management at TCT 2024

The California-based company, fresh off receiving expanded Medicare coverage and a new Category I CPT code for its AI offerings, will have a significant presence at TCT 2024. 

TCT 2023 crowd

CRF announces late-breaking clinical trials for TCT 2024

The Cardiovascular Research Foundation has announced 10 late-breaking clinical trials and 15 late-breaking clinical science sessions for TCT 2024 in Washington, DC. Topics will include TAVR and other structural heart procedures, artificial intelligence and much more. 

With a growing shortage of cardiologists in the U.S., there is growing interest recruiting more clinicians from overseas. But there are barriers to this, approach explained Abdel Almanfi, MD, FACC, FSCAI, a structural heart interventional cardiologist at Baylor St. Luke's Medical Center in Houston, Texas. He spoke with Cardiovascular Business and shared his journey from Libya to the United States, shedding light on the challenges foreign doctors face in realizing their dreams of practicing in America.

Cardiologist shares his long journey from Libya to United States

Abdel Almanfi, MD, went through years of training in Libya, but then he had to start over once he landed in the United States. 

Boston Scientific’s Agent Drug-Coated Balloon (DCB), which delivers a therapeutic dose of the anti-proliferative drug paclitaxel to the patient’s scar tissue to prevent ISR from recurring, gained FDA approval on March 1..

Cardiologists share historic research that led to FDA’s long-awaited approval of coronary DCB

When Boston Scientific’s coronary DCB gained approval in the United States, it was a moment the country's cardiologists had been looking forward to for years. The cardiologists who researched the device have now detailed their findings, highlighting the "unmet need" this technology is addressing. 

Carrie Redick RN MSN NEA-BC, director of interventional cardiology and structural heart, Morristown Medical Center, Atlantic Health System, explains the need for financial literacy among structural heart program directors at the Transcatheter Cardiovascular therapeutics (TCT) 2023 meeting.

Why financial literacy is so important for structural heart program directors

Carrie Redick, an ICU nurse for nearly 20 years, said understanding more about financial data improved her ability to acquire funding and other resources for her program when necessary. 

Video of Patricia Keegan, NP, Emory, explains value of the ACC TVT NCDR registry for TAVR and why it is important from both a quality monitoring standpoint and for attracting patients to your program.

Data registries have been a huge success for U.S. structural heart programs

ACC/STS National Cardiovascular Data Registry metrics reporting for TAVR is important for marketing and care quality, explains Patricia Keegan, NP, with the Emory Heart and Vascular Center.

CroíValve DUO device tricuspid valve

CroíValve kicks off early feasibility study for new TR device, names cardiologist Martin Leon to advisory board

The company hopes to enroll 15 patients to monitor the safety and effectiveness of its new-look transcatheter device for severe tricuspid regurgitation. 

Displaying 33 - 40 of 138

Around the web

Health Imaging
Tariffs will have a significant impact on the nuclear imaging supply chain in the US

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.

Radiology Business
U.S. iodine contrast supply may not be subject to proposed 25% tariffs

If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. depending what rules are put in place.